For Tyrer–Cuzick v8, screen-detected, invasive, in situ, ER- and PR-positive, and stage 2 or later breast cancers had significantly lower AUCs (3.7–25.8 percentage points) compared with the imaging-only model at one or several years in the 1–10-year follow-up (Figure 3, Table A4). The gene discussed is ESR1; the disease is breast cancer.